Literature DB >> 11131457

Clinical diagnostic scale: a useful tool in the evaluation of suspected hepatotoxic adverse drug reactions.

G P Aithal1, M D Rawlins, C P Day.   

Abstract

BACKGROUND/AIM: Due to an absence of specific markers, the diagnosis of drug-induced hepatotoxicity is necessarily based on circumstantial evidence and is often inaccurate. We have evaluated the use of the clinical diagnostic scale (CDS) in the causality assessment of hepatotoxic adverse drug reaction (ADR) reports.
METHODS: 135 hepatic adverse ADRs reported to the Committee on Safety of Medicines in North East England 1992-6 were evaluated. Initially, "International Consensus Criteria" were used to classify reactions as "drug-related", "drug-unrelated" and "indeterminate". Using the CDS, each ADR was then categorised as either definite drug hepatotoxicity (score >17), probable (14-17), possible (10-13), unlikely (6-9), or drug hepatotoxicity excluded (<6).
RESULTS: 49 ADRs were considered drug-related, 65 unrelated and 21 indeterminate. Reports classified as drug-related by consensus criteria scored higher on the CDS, with a median score of 12, range: 8-15, than either the indeterminate (8; [3-12]) or drug-unrelated reports (5; [2-11]) (p<0.0001). A CDS score of >9, identified 88% of the cases classified as drug-related hepatotoxicity by consensus criteria and excluded 98% of those unrelated to the drugs.
CONCLUSIONS: CDS scoring correlates well with the international consensus classification and may be a useful tool in the routine evaluation of suspected hepatotoxic drug reactions.

Entities:  

Mesh:

Year:  2000        PMID: 11131457     DOI: 10.1016/s0168-8278(00)80127-0

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  19 in total

Review 1.  Liver enzyme alteration: a guide for clinicians.

Authors:  Edoardo G Giannini; Roberto Testa; Vincenzo Savarino
Journal:  CMAJ       Date:  2005-02-01       Impact factor: 8.262

2.  Acute liver injury associated with the use of herbal preparations containing glucosamine: three case studies.

Authors:  Aileen Smith; John Dillon
Journal:  BMJ Case Rep       Date:  2009-09-02

3.  CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis.

Authors:  Nicolas Vuilleumier; Michel F Rossier; Alberto Chiappe; Florence Degoumois; Pierre Dayer; Bernadette Mermillod; Laurent Nicod; Jules Desmeules; Denis Hochstrasser
Journal:  Eur J Clin Pharmacol       Date:  2006-04-27       Impact factor: 2.953

4.  Hypertransaminasemia in childhood as a marker of genetic liver disorders.

Authors:  Raffaele Iorio; Angela Sepe; Antonietta Giannattasio; Francesco Cirillo; Angela Vegnente
Journal:  J Gastroenterol       Date:  2005-08       Impact factor: 7.527

5.  Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop.

Authors:  Robert J Fontana; Leonard B Seeff; Raúl J Andrade; Einar Björnsson; Christopher P Day; Jose Serrano; Jay H Hoofnagle
Journal:  Hepatology       Date:  2010-08       Impact factor: 17.425

6.  Drug-induced Liver Injury.

Authors:  Stefan David; James P Hamilton
Journal:  US Gastroenterol Hepatol Rev       Date:  2010-01-01

Review 7.  [Morphology of drug induced liver damage].

Authors:  H-U Kasper; U Drebber; I Hirsch; H P Dienes
Journal:  Pathologe       Date:  2006-05       Impact factor: 1.011

Review 8.  Drug and herb induced liver injury: Council for International Organizations of Medical Sciences scale for causality assessment.

Authors:  Rolf Teschke; Albrecht Wolff; Christian Frenzel; Alexander Schwarzenboeck; Johannes Schulze; Axel Eickhoff
Journal:  World J Hepatol       Date:  2014-01-27

Review 9.  Practical guidelines for diagnosis and early management of drug-induced liver injury.

Authors:  Kazuto Tajiri; Yukihiro Shimizu
Journal:  World J Gastroenterol       Date:  2008-11-28       Impact factor: 5.742

Review 10.  Persistent hypertransaminasemia in asymptomatic children: a stepwise approach.

Authors:  Pietro Vajro; Sergio Maddaluno; Claudio Veropalumbo
Journal:  World J Gastroenterol       Date:  2013-05-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.